Selection of advanced kidney cancer patients for nephrectomhy

In this study, 6,043 patients with metastatic renal cell carcinoma (RCC) had a nephrectomy while 489 did not and were follow-up. Age, stage, presence of metastases and tumour size were assessed. The study showed that there was no survival benefit for patients with stage T4 disease and metastases or older than 76 years of age […]

read more

Surgery after targeted therapy or immunotherapy for metastatic kidney cancer

A recent retrospective study (looking back at the patients’ cases after treatment had occurred) has shown that patients with metastatic renal cell carcinoma (RCC) who were treated with targeted therapy, such as sunitinib or pazopanib, or immunotherapy, such as nivolumab, had better survival outcomes if went on to have surgery to remove the kidney. This […]

read more

Evidence in favour of active surveillance for small renal masses

Two studies presented at the American Urological Association 2020 Virtual Experience this month provide evidence that active surveillance for small renal masses among older patients is as effective as surgery in terms of survival for patients with suspected renal cell carcinoma (RCC). In a study from Oxford University Hospitals 208 patients with 212 T1a small […]

read more

Female kidney cancer patients undergoing surgery for non-metastatic disease may have more favourable prognosis

A retrospective analysis of over 2000 patients from the International Marker Consortium for Renal Cancer (INMARC) database showed that female patients with non-metastatic clear cell renal cell carcinoma (ccRCC) had lower grade, lower stage, and longer relapse-free survival after partial or radical nephrectomy for their cancer. In conclusion, this study suggests that female patients with […]

read more

ASCO GU 2020: Nephrectomy linked to longer overall survival in patients treated with immunotherapy or targeted therapy for advanced kidney cancer

Surgery to remove the kidney tumour is often the preferred treatment for people with kidney cancer that has not spread. Recently, doctors have been questioning whether it is beneficial to operate to remove the kidney tumour in patients with kidney cancer that has already spread beyond the kidney. Immunotherapies for advanced kidney cancer include drugs […]

read more

Nephrectomy after complete response to immunotherapy

A retrospective study looked at the clinical and surgical outcomes in 11 patients with metastatic clear cell renal cell carcinoma (RCC) who had a delayed nephrectomy following a complete response to immunotherapy or immunotherapy and targeted therapy combinations. There were surgical difficulties in 81.8% of cases caused by adhesions and inflammatory reactions. At 15 months […]

read more

A potential biomarker for survival for non-metastatic kidney cancer

A recent study published in the journal International Urology and Nephrology this month evaluates mean platelet volume-to-lymphocyte ratio (MPVLR) as a biomarker for survival in patients undergoing nephrectomy for non-metastatic clear cell renal cell carcinoma (ccRCC). In the study, 344 patients with proven ccRCC that has not spread (non-metastatic) were treated with radical or partial […]

read more

Association of anxiety and depression with outcomes for kidney cancer patients undergoing nephrectomy

A recent retrospective study of 1990 adults who had a radical or partial nephrectomy for clear cell renal cell carcinoma (RCC) looked at the association between anxiety or depression and survival. Patients with anxiety or depression prior to or at the time of surgery (197 patents, 10%) had significantly more complications 30 days after surgery. […]

read more

Kidney cancer surgery in older patients

The RESURGE project retrospectively analysed data from three published studies including 1871 patients with renal cell carcinoma (RCC) from 24 hospitals. This study looked at outcomes of surgery (radical or partial nephrectomy) in older patients aged over 75 years. The study concluded that surgery for kidney cancer is feasible and safe in well-selected older patients. […]

read more

Is there a role for cytoreductive nephrectomy?

This discussion with Dr Paul Russo presents a case for cytoreductive nephrectomy, despite the results from the CARMENA trial, which did not show an overall survival advantage. The report concludes that careful selection of patients with intermediate-risk (not poor-risk) metastatic renal cell carcinoma (RCC) and cytoreductive nephrectomy performed by experienced surgeons, followed by treatment with […]

read more
Showing 1 to 10 of 21 results
  TOP